Literature DB >> 10547435

Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.

M Isaka1, Y Yasuda, S Kozuka, T Taniguchi, K Matano, J Maeyama, T Komiya, K Ohkuma, N Goto, K Tochikubo.   

Abstract

Nasal mucosal immunization is very attractive for vaccination to prevent various bacterial and viral infectious diseases because of induction of systemic and mucosal immune responses. The aim of the present study was to investigate the possibility of changing the immunization procedure of diphtheria toxoid (DT) from intramuscular or subcutaneous injection to intranasal administration. Intranasal immunization with aluminium-non-adsorbed diphtheria toxoid (nDT) together with recombinant cholera toxin B subunit (rCTB, 10 microg) induced, at a concentration of 5 Lf, high levels of serum DT-specific IgG antibody responses and high or moderate levels of the specific IgA antibody responses in all mice and only a slight level of the specific IgE antibody responses in some mice. Furthermore, sufficiently high diphtheria antitoxin titres more than 0.1 international units (IU) ml(-1) were obtained from mice which showed high levels of serum DT-specific IgG antibody responses. Under the same experimental conditions, induction of significant levels of mucosal DT-specific IgA antibody responses occurred in the nasal cavity, the lung, the saliva and vaginal secretions and the small and large intestines of all mice, although there were different titres between individual mice. Similar results were also obtained with rCTB-specific serum IgG and IgA and mucosal IgA antibody responses; serum rCTB-specific IgE antibody titres were not detected. These results show that intranasal administration of nDT with rCTB must be a very useful means for vaccination against diphtheria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547435     DOI: 10.1016/s0264-410x(99)00258-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.

Authors:  Mari Ohmura; Masafumi Yamamoto; Chikako Tomiyama-Miyaji; Yoshikazu Yuki; Yoshifumi Takeda; Hiroshi Kiyono
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

3.  Induction of immune responses in mice after oral immunization with recombinant Lactobacillus casei strains expressing enterotoxigenic Escherichia coli F41 fimbrial protein.

Authors:  Jian-Kui Liu; Xi-Lin Hou; Chun-Hua Wei; Li-Yun Yu; Xiao-Jie He; Gui-Hua Wang; Jong-Soo Lee; Chul-Joong Kim
Journal:  Appl Environ Microbiol       Date:  2009-05-15       Impact factor: 4.792

4.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

5.  Inhibition of T-cell response by Escherichia coli heat-labile enterotoxin-treated epithelial cells.

Authors:  L M Lopes; A Maroof; G Dougan; B M Chain
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 6.  CpG oligodeoxynucleotides as mucosal adjuvants.

Authors:  Sumiko Iho; Jun-ichi Maeyama; Fumiko Suzuki
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity.

Authors:  Jun-ichi Maeyama; Hisakazu Takatsuka; Fumiko Suzuki; Ayumi Kubota; Satomi Horiguchi; Takako Komiya; Ichiroh Shimada; Eri Murata; Youko Osawa; Harukazu Kitagawa; Takasumi Matsuki; Masanori Isaka; Saburo Yamamoto; Sumiko Iho
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

8.  Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A.

Authors:  Wyatt Byrd; Steven R Mog; Frederick J Cassels
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.